NCT06514144View on ClinicalTrials.gov

Exacerbations Among Patients Receiving Breztri (EROS Study)

CompletedOBSERVATIONAL

Enrollment

2,409

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions

Pulmonary DiseaseChronic ObstructiveRetrospective Studies

Interventions

DRUG

BGF

budesonide/glycopyrrolate/formoterol fumarate

Trial Locations (1)

19850

AstraZeneca, Wilmington

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY